Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22345623 | 0.89 | ELANE (0.49) | ELANEKMT2AATMKDM4EMEN1 | |
| SCHEMBL22352929 | 0.85 | ELANE (0.37) | ELANEKMT2AATMKDM4EMEN1 | |
| SCHEMBL22352941 | 0.83 | ELANE (0.44) | ELANEKMT2AATMKDM4EMAPT | |
| SCHEMBL22353034 | 0.83 | ELANE (0.51) | ELANEKMT2AATMMEN1LMNA | |
| SCHEMBL27053111 | 0.82 | ELANE (0.41) | ELANEKMT2AATMMAPT | |
| SCHEMBL9607826 | 0.81 | ELANE (0.45) | ELANEKMT2AATMKDM4EMEN1 | |
| SCHEMBL22353041 | 0.81 | ELANE (0.46) | ELANEKMT2AATMLMNAMAPT | |
| SCHEMBL22352782 | 0.80 | ELANE (0.36) | ELANEKMT2AATM | |
| SCHEMBL5831972 | 0.79 | ELANE (0.56) | ELANEKMT2AATMKDM4EMEN1 | |
| SCHEMBL22353025 | 0.78 | MAPT (0.41) | ELANEKMT2AATMKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685863-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11685863-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20220127532-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127532-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | LPXN, VCL, LCP1 | ELANE 1153/4885KMT2A 2566/4885ATM 1563/4885 |
| US-11685863-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | LPXN, VCL, LCP1 | ELANE 1153/4885KMT2A 2566/4885ATM 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.